Request availability and a quotation for your required quantity and destination.
| Product | Tirzepatide 7.5 mg - Mounjaro KwikPen |
|---|---|
| Categories | Weight Loss |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Active ingredient: Tirzepatide
Strength: 7.5 mg per weekly dose
Presentation: Multi-dose prefilled KwikPen, four doses per pen
Medicine class: Dual GIP/GLP-1 receptor agonist
Prescription: Required
Mounjaro 7.5 mg KwikPen contains tirzepatide for once-weekly subcutaneous injection. In the UK, Mounjaro has approved uses in type 2 diabetes and, for eligible adults, weight management alongside dietary and activity measures. Indications vary by country: approval for weight management must not be assumed everywhere. The 7.5 mg pen is not appropriate as a first dose for someone new to tirzepatide.
Tirzepatide activates GIP and GLP-1 receptors, supporting glucose-dependent insulin secretion and influencing appetite, satiety and food intake. Outcomes vary according to individual clinical factors, dose tolerability and wider care.
This is a dose-escalation strength, not the starting dose. If a dose increase is appropriate, approved guidance uses 2.5 mg increments after at least four weeks on the current dose. The adult maximum is 15 mg weekly. Never skip titration stages or increase without prescriber supervision.
Unlike a single-dose vial, the multi-dose KwikPen contains four prescribed weekly doses. Patients need instruction on using the specific pen, fitting a new compatible needle and rotating injection sites. Do not share a pen, even after changing needles, or attempt to extract excess solution. Follow the manufacturer’s storage and disposal directions, including after first use.
Common effects include nausea, diarrhoea, vomiting, constipation and abdominal discomfort, particularly during escalation. Clinically important risks include pancreatitis, gallbladder disease, dehydration-related kidney injury and hypoglycaemia when used with insulin or certain diabetes medicines. The U.S. label warns about thyroid C-cell tumors in rodents and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN2. Discuss pregnancy, oral contraceptive interactions and planned anaesthesia or sedation with your prescriber. Seek urgent care for severe, persistent abdominal pain or a serious allergic reaction.
Mounjaro 2.5 mg · Mounjaro 5 mg · Mounjaro 7.5 mg · Mounjaro 10 mg · Mounjaro 12.5 mg · Mounjaro 15 mg
See the UK Mounjaro KwikPen Summary of Product Characteristics for indications, dose schedules, product presentation and safety details.
The multi-dose presentation contains four weekly doses. Confirm the pack and local product leaflet.
No. Initial dosing begins at a lower strength, and dose increases require appropriate medical supervision.
These products have different ingredients, dosing and indications. Any change requires the prescribing clinician.
Yes, enquiries can be submitted. Supply depends on prescription rules, product availability, cold-chain feasibility and destination-country requirements.
Cureiva Healthcare assists with medicine information and legitimate international enquiries. This material is educational, not a personal prescribing recommendation. References checked October 2026; independent physician sign-off has not been claimed.